The Gut Microbiota-Related Antihyperglycemic Effect of Metformin
It is critical to sustain the diversity of the microbiota to maintain host homeostasis and health. Growing evidence indicates that changes in gut microbial biodiversity may be associated with the development of several pathologies, including type 2 diabetes mellitus (T2DM). Metformin is still the fi...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-01-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/18/1/55 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832587736579571712 |
|---|---|
| author | Izabela Szymczak-Pajor Józef Drzewoski Małgorzata Kozłowska Jan Krekora Agnieszka Śliwińska |
| author_facet | Izabela Szymczak-Pajor Józef Drzewoski Małgorzata Kozłowska Jan Krekora Agnieszka Śliwińska |
| author_sort | Izabela Szymczak-Pajor |
| collection | DOAJ |
| description | It is critical to sustain the diversity of the microbiota to maintain host homeostasis and health. Growing evidence indicates that changes in gut microbial biodiversity may be associated with the development of several pathologies, including type 2 diabetes mellitus (T2DM). Metformin is still the first-line drug for treatment of T2DM unless there are contra-indications. The drug primarily inhibits hepatic gluconeogenesis and increases the sensitivity of target cells (hepatocytes, adipocytes and myocytes) to insulin; however, increasing evidence suggests that it may also influence the gut. As T2DM patients exhibit gut dysbiosis, the intestinal microbiome has gained interest as a key target for metabolic diseases. Interestingly, changes in the gut microbiome were also observed in T2DM patients treated with metformin compared to those who were not. Therefore, the aim of this review is to present the current state of knowledge regarding the association of the gut microbiome with the antihyperglycemic effect of metformin. Numerous studies indicate that the reduction in glucose concentration observed in T2DM patients treated with metformin is due in part to changes in the biodiversity of the gut microbiota. These changes contribute to improved intestinal barrier integrity, increased production of short-chain fatty acids (SCFAs), regulation of bile acid metabolism, and enhanced glucose absorption. Therefore, in addition to the well-recognized reduction of gluconeogenesis, metformin also appears to exert its glucose-lowering effect by influencing gut microbiome biodiversity. However, we are only beginning to understand how metformin acts on specific microorganisms in the intestine, and further research is needed to understand its role in regulating glucose metabolism, including the impact of this remarkable drug on specific microorganisms in the gut. |
| format | Article |
| id | doaj-art-c37d4ec8d77242c9943bccb911e224c9 |
| institution | Kabale University |
| issn | 1424-8247 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceuticals |
| spelling | doaj-art-c37d4ec8d77242c9943bccb911e224c92025-01-24T13:45:12ZengMDPI AGPharmaceuticals1424-82472025-01-011815510.3390/ph18010055The Gut Microbiota-Related Antihyperglycemic Effect of MetforminIzabela Szymczak-Pajor0Józef Drzewoski1Małgorzata Kozłowska2Jan Krekora3Agnieszka Śliwińska4Department of Nucleic Acid Biochemistry, Medical University of Lodz, 251 Pomorska Str., 92-213 Lodz, PolandCentral Teaching Hospital of the Medical University of Lodz, 251 Pomorska Str., 92-213 Lodz, PolandDepartment of Nucleic Acid Biochemistry, Medical University of Lodz, 251 Pomorska Str., 92-213 Lodz, PolandCentral Teaching Hospital of the Medical University of Lodz, 251 Pomorska Str., 92-213 Lodz, PolandDepartment of Nucleic Acid Biochemistry, Medical University of Lodz, 251 Pomorska Str., 92-213 Lodz, PolandIt is critical to sustain the diversity of the microbiota to maintain host homeostasis and health. Growing evidence indicates that changes in gut microbial biodiversity may be associated with the development of several pathologies, including type 2 diabetes mellitus (T2DM). Metformin is still the first-line drug for treatment of T2DM unless there are contra-indications. The drug primarily inhibits hepatic gluconeogenesis and increases the sensitivity of target cells (hepatocytes, adipocytes and myocytes) to insulin; however, increasing evidence suggests that it may also influence the gut. As T2DM patients exhibit gut dysbiosis, the intestinal microbiome has gained interest as a key target for metabolic diseases. Interestingly, changes in the gut microbiome were also observed in T2DM patients treated with metformin compared to those who were not. Therefore, the aim of this review is to present the current state of knowledge regarding the association of the gut microbiome with the antihyperglycemic effect of metformin. Numerous studies indicate that the reduction in glucose concentration observed in T2DM patients treated with metformin is due in part to changes in the biodiversity of the gut microbiota. These changes contribute to improved intestinal barrier integrity, increased production of short-chain fatty acids (SCFAs), regulation of bile acid metabolism, and enhanced glucose absorption. Therefore, in addition to the well-recognized reduction of gluconeogenesis, metformin also appears to exert its glucose-lowering effect by influencing gut microbiome biodiversity. However, we are only beginning to understand how metformin acts on specific microorganisms in the intestine, and further research is needed to understand its role in regulating glucose metabolism, including the impact of this remarkable drug on specific microorganisms in the gut.https://www.mdpi.com/1424-8247/18/1/55glucose-lowering effectinsulin resistance (IR)metforminmicrobiotatype 2 diabetes mellitus (T2DM) |
| spellingShingle | Izabela Szymczak-Pajor Józef Drzewoski Małgorzata Kozłowska Jan Krekora Agnieszka Śliwińska The Gut Microbiota-Related Antihyperglycemic Effect of Metformin Pharmaceuticals glucose-lowering effect insulin resistance (IR) metformin microbiota type 2 diabetes mellitus (T2DM) |
| title | The Gut Microbiota-Related Antihyperglycemic Effect of Metformin |
| title_full | The Gut Microbiota-Related Antihyperglycemic Effect of Metformin |
| title_fullStr | The Gut Microbiota-Related Antihyperglycemic Effect of Metformin |
| title_full_unstemmed | The Gut Microbiota-Related Antihyperglycemic Effect of Metformin |
| title_short | The Gut Microbiota-Related Antihyperglycemic Effect of Metformin |
| title_sort | gut microbiota related antihyperglycemic effect of metformin |
| topic | glucose-lowering effect insulin resistance (IR) metformin microbiota type 2 diabetes mellitus (T2DM) |
| url | https://www.mdpi.com/1424-8247/18/1/55 |
| work_keys_str_mv | AT izabelaszymczakpajor thegutmicrobiotarelatedantihyperglycemiceffectofmetformin AT jozefdrzewoski thegutmicrobiotarelatedantihyperglycemiceffectofmetformin AT małgorzatakozłowska thegutmicrobiotarelatedantihyperglycemiceffectofmetformin AT jankrekora thegutmicrobiotarelatedantihyperglycemiceffectofmetformin AT agnieszkasliwinska thegutmicrobiotarelatedantihyperglycemiceffectofmetformin AT izabelaszymczakpajor gutmicrobiotarelatedantihyperglycemiceffectofmetformin AT jozefdrzewoski gutmicrobiotarelatedantihyperglycemiceffectofmetformin AT małgorzatakozłowska gutmicrobiotarelatedantihyperglycemiceffectofmetformin AT jankrekora gutmicrobiotarelatedantihyperglycemiceffectofmetformin AT agnieszkasliwinska gutmicrobiotarelatedantihyperglycemiceffectofmetformin |